Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7337 for Contrast Enhancement in Liver CT
NCT00280410Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2006
- Primary completion
- Oct 2006
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iomeprol in Liver lesion, sponsored by Eisai Co., Ltd. Primary endpoint: Contrast enhancement effect on tumor-like lesions in the liver. Started Feb 2006; status: completed.
02
Drugs
iomeprol
03
Conditions
Liver lesion
Beyond the preview
Go deeper on NCT00280410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280410.